Hosted on MSN1mon
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's WhyCibotercept is an investigational modified ActRIIB fusion protein. The phase II TROPOS study is evaluating three doses of cibotercept (1.5 mg/kg, 3 mg/kg and 4.5 mg/kg) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback